15 results
Webinar
Trends in Pharmaceutical Patents and the Potential Impact of Exclusivity Trends in Pharmaceutical Patents and the Potential Impact of Exclusivity
November 17, 2020
Webinar
IP Health Blog
FDA Final Guidance on Submitting an ANDA or a 505(b)(2) FDA Final Guidance on Submitting an ANDA or a 505(b)(2)
May 14, 2019
IP Health Blog
FDA Commissioner Statement about the Orange Book FDA Commissioner Statement about the Orange Book
February 7, 2019
IP Health Blog
FDA Guidance on Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease FDA Guidance on Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease
December 15, 2017
IP Health Blog
FDA Guidance on Whether to Submit an ANDA or 505(b)(2) Application FDA Guidance on Whether to Submit an ANDA or 505(b)(2) Application
October 14, 2017
Articles
FDA Amends Regulations for 505(b)(2) Applications and ANDAs—Part II FDA Amends Regulations for 505(b)(2) Applications and ANDAs—Part II
October 2017
Intellectual Property & Technology Law JournalDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.